20th Nov 2006 07:02
Hikma Pharmaceuticals Plc20 November 2006 NOTIFICATION OF SITE VISIT London, 20 November 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), themultinational pharmaceuticals group, is hosting a site visit in Sintra, Portugaltoday. Hikma will provide an overview of its core businesses as well as a tour of itsInjectable manufacturing facilities, which include the new state-of-the-artcephalosporin plant. No material new information will be disclosed and there will not be any furtherstatement on current trading. Copies of today's presentations will be posted onthe company's website, www.hikma.com. - ENDS - Enquiries:Hikma Pharmaceuticals PLC Susan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals